.png)
ORLANDO, Fla. — The interleukin (IL)-4 and IL-13 inhibitor dupilumab improved itch symptoms and curtailed disease activity while also reducing oral corticosteroid use in older patients with bullous pemphigoid (BP), a phase 2/3 study demonstrated. “Dupilumab demonstrated significant benefits across multiple disease aspects in BP at 36 weeks...
2931 Ridge Road Ste 101-1020 Rockwall, Texas 75032
+012 345 67890
LeadershipLending@gmail.com
Copyright © 2023 locksmith. All Rights Reserved
